The World Health Organization has declared coronavirus 2019 (COVID-19) a global pandemic. Healthcare providers should prepare internal guidelines covering all aspect of the organization in order to have their unit ready as soon as possible. This document addresses the current COVID-19 pandemic for maternal-fetal medicine practitioners.
The goals of the guidelines put forth here are 2-fold: first, to reduce patient risk through health care exposure, understanding that asymptomatic health systems/health care providers may become the most common vector for transmission, and second, to reduce the public health burden of COVID-19 transmission throughout the general population.
Box 1 outlines general guidance to prevent the spread of COVID-19 and protect our obstetric patients. Section 1 outlines suggested modifications of outpatient obstetrical (prenatal) visits. Section 2 details suggested scheduling of obstetrical ultrasound. Section 3 reviews suggested modification of nonstress tests (NSTs) and biophysical profiles (BPPs). Section 4 reviews suggested visitor policy for obstetric outpatient office. Section 5 discusses the role of trainees and medical education in the setting of a pandemic. These are suggestions, which can be adapted to local needs and capabilities. Guidance is changing rapidly, so please continue to watch for updates.
Box 1.
General obstetric/MFM COVID-19 recommendations
|
ACOG, American College of Obstetrics and Gynecology; CDC, Centers for Disease Control and Prevention; COVID-19, coronavirus 2019; ISUOG, International Society of Ultrasound in Obstetrics and Gynecology; L&D,labor and delivery; MFM, maternal-fetal medicine; SMFM, Society for Maternal-Fetal Medicine; WHO, World Health Organization.
Boelig. MFM guidance for COVID-19. Am J Obstet Gynecol MFM 2020.
Section 1: Outpatient obstetrical (prenatal) visits
All new obstetrical intakes should be completed by telehealth/remotely unless the patient describes an urgent problem, in which case she will be appointed as an urgent in-person visit. The standard timing for in-person encounters in routine, uncomplicated pregnancies are described in Table 1 . The hope is that necessary laboratory work and/or ultrasounds can be done at the same visit.
Table 1.
Gestational age | In-person OB visit | Ultrasound | Comments |
---|---|---|---|
<11 weeksa | Telephone OB intake | ||
11–13 weeksb | X | X (dating/NT) | Initial OB lab tests |
20 weeks | X | X (anatomy) | |
28 weeks | X | Labs/vaccines | |
32 weeks | X (if indicated) | Telehealth | |
36 weeks | X | X (if indicated) | GBS/HIV screen |
37 weeks to delivery | Weekly telehealth and kick counts | ||
Postpartum | Telehealth |
Use of telehealth visits facilitate blood pressure cuff/kick counts at home so that in-person visits are not necessary. Additional visits including diabetes control, hypertension, mood disorder, etc may be done remotely with teleheath as well.
COVID-19, coronavirus 2019; GBS, group B strep; NT, nuchal translucency; OB, obstetric.
Boelig. MFM guidance for COVID-19. Am J Obstet Gynecol MFM 2020.
Earlier scan may be indicated if at risk for ectopic
If viability is previously established, consider skipping 11–13 week scan and offering cell-free DNA.
Consideration may also be given to having laboratory work performed at lower-volume satellite office sites in which the ability to accomplish social distancing is more easily attained, as feasible. Interim telehealth visits can be scheduled at provider discretion (eg, at 16, 24, 34 weeks). Reschedule all obstetric visits using this paradigm.
To minimize other in-patient visits, all patients should be instructed to obtain blood pressure cuffs if feasible. Some more health plans may cover the cost of blood pressure cuffs in the setting of the coronavirus pandemic. Consider all other visits by telehealth if feasible. Postpartum evaluation of cesarean wound healing or mastitis concerns may be optimized through the use of photo upload options available in many electronic medical record patient portal programs.
Section 2: Scheduling of obstetric ultrasound
Box 2 summarizes our suggested modifications to ultrasound timing. Table 2 outlines recommendations for specific antenatal indications. We recognize that these recommendations are specific to our practice environment. Maternal-fetal medicine physicians nationally and internationally should feel empowered to adjust as needed based on limitations in capacity and/or higher incidence of COVID, which may require further restrictions for both patient safety and public health.
Box 2.
Dating ultrasound:
|
NT, nuchal translucency; LMP, last menstrual period; EGA, estimated gestational age; BMI, body mass index; q, every.
aOr earlier if desired based on state-specific termination laws.
bConsider forgoing follow-up ultrasound for 1 or 2 suboptimal views (eg, l/s spine not seen well because of fetal position but posterior fossa normal).
Boelig. MFM guidance for COVID-19. Am J Obstet Gynecol MFM 2020.
Table 2.
Indication | Frequency |
Comments | ||
---|---|---|---|---|
Once | q 4 wks | q 6–8 wks | ||
Pregestational diabetes mellitus | X | |||
Chronic HTN on medications | X | Once if no meds | ||
Current preeclampsia/gestational HTN | X | |||
History of severe preeclampsia | X | |||
History of IUGR or SGA | X | |||
Current IUGR | X | |||
Sickle cell disease | X | |||
CKD | X | |||
Multiples, mono/dia | X | |||
Multiples, mono/mono | X | |||
Multiples, di/di | X | |||
GDMA2 | X | |||
Lupus, no renal dysfunction | X | |||
Prior unexplained IUFD | X | |||
Organ transplant | X | |||
Maternal cardiac disease | X | |||
Uncontrolled thyroid disease | X | |||
Current tobacco or substance use | X | |||
AMA (≥35 y old) | X | |||
Gestational diabetes, A1 | X | |||
Chronic HTN, off medications | X | |||
Abnormal placentation | X | At 34–36 wks | ||
Uterine fibroids >5 cm | X |
Serial growth ultrasound beginning at 28 weeks; 1 time growth at 32 weeks unless otherwise indicated. Practice locations should adjust as needed based on site capacity and risk of COVID exposure.
AMA, advanced maternal age; CKD, chronic kidney disease; COVID-19, coronavirus 2019; Di/Di, dichorionic diamniotic; GDMA2, gestational diabetes-A2; HTN, hypertension; ; IUFD, intrauterine fetal demise IUGR,intrauterine growth restriction; Mono-Di, monochorionic diamniotic; Mono/Mono, monochorionic diamniotic; q, every; SGA, small for gestational age.
Boelig. MFM guidance for COVID-19. Am J Obstet Gynecol MFM 2020.
Consider every 2 week twin-twin transfusion screening.
In addition to modifying ultrasound timing, the routine practice of face-to-face counseling for ultrasounds should be adjusted. In most cases ultrasound findings can be reviewed either over the phone/telehealth, or in the setting of a normal routine ultrasound, by the obstetric provider at the next visit. Indeed, because of resource limitations, many sites do only have remote communications for ultrasound finding, and this technology should be adapted widely to limit unnecessary patient contact, which protects both the patient from getting an infection and the provider from being a vector.
Section 3: Scheduling of nonstress tests/biophysical profiles
Table 3 illustrates how antenatal surveillance with NSTs/BPPs may be modified in the setting of the COVID-19 pandemic and the actual increased risk patients may face in coming into the office for 30 or more minutes of testing. In general, we suggest the following principles:
-
•
Twice-weekly NSTs only for intrauterine growth restriction with abnormal umbilical artery Doppler.
-
•
Limit NSTs initiated <32 weeks.
-
•
If concurrent ultrasound, perform a BPP rather than an additional NST visit.
-
•
In lower-risk patients, such as advanced maternal age 35–39 years or body mass index >40 kg/m2 with no other comorbidities, consider kick counts instead of NSTs.
Table 3.
Indication for NST | Gestational age to begin 1 time/wk | Gestational age to begin 2 times/wk | Comments | COVID-19a |
---|---|---|---|---|
AMA | 36 | Fetal kick counts instead of NST | ||
Cholestasis | Diagnosis | |||
Decreased fetal movement | Diagnosis | One time only | ||
Pregestational diabetes | 32 | 36 | Weekly only | |
GDMA2 | 32 | 36 | Weekly only | |
Chronic HTN | 32 | 36 weeks if no medications | ||
Gestational HTN | Diagnosis | Weekly with home BP monitoring | ||
Preeclampsia | Diagnosis | Weekly with home BP monitoring | ||
CKD | 32 | |||
IUGR | Diagnosis | Weekly with Doppler. Substitute BPP when possible | ||
Elevated Dopplers | Diagnosis | |||
SLE | 32 | |||
Fetal arrhythmia | Diagnosis | |||
Mono/Di twins | 32 | |||
Di/Di twins | Only if additional indication | |||
Obesity/BMI >40 kg/m2 | 32 | Fetal kick counts instead of NST | ||
Oligohydramnios | Diagnosis | |||
Polyhydramnios | Diagnosis | Diagnosis or at 32 wks if <32 wk diagnosis. Only for AFI >30 | ||
Prior IUFD | 32 | 1 wk prior to IUFD | ||
Sickle cell disease | 32 | Kick counts if well controlled | ||
Single umbilical artery | 32 | Fetal kick counts if normal growth, normal anatomy, normal genetic screening |
AMA, advanced maternal age; BMI, body mass index; BP, blood pressure; BPP, biophysical profile; CKD, chronic kidney diseases; COVID-19, coronavirus 2019; Di/Di, dichorionic diamniotic; GDMA2, gestational diabetes-A2; HTN, hypertension; ; IUFD, intrauterine fetal demise IUGR, intrauterine growth restriction; Mono-Di, monochorionic diamniotic; NST, nonstress test; SLE, systemic lupus erythematosus.
Boelig. MFM guidance for COVID-19. Am J Obstet Gynecol MFM 2020.
Text in column indicates changes to recommendations in setting of COVID, and no change in practice is suggested if this column is empty.
For patients with gestational hypertension/preeclampsia, plan a weekly visit in the office with daily blood pressure checks at home. Weekly visit will include antenatal testing, blood pressure check, and labwork drawn in the office to minimize the need for additional visits. These changes should be relayed to patients with a discussion of the altered risk/benefit balance of coming to the office for testing in the setting of a global pandemic.
Section 4: Visitor policy for obstetric outpatient office
Box 3 outlines the general guidelines for visitors. In the setting of a pandemic, consider visitors as something that does not benefit patient care but may harm other patients/providers. Exceptions may be made when the visitor is critical for patient care, for example, for young patients coming with a parent or someone with developmental delay who relies on a support person to aid in medical decision making.
Box 3.
General outpatient office visitor policy
|
Boelig. MFM guidance for COVID-19. Am J Obstet Gynecol MFM 2020.
Section 5: Involvement of trainees
In setting of a COVID-19 and the significant risk of not only trainees’ health but also additional health care providers serving as a vector and using limited protective equipment, we suggest all nonessential clinical personnel remain at home. This means any nursing, medical, or sonography students should not be in the office; any other observerships should be suspended. Additionally, in an academic setting in which an attending physician is supervising residents or fellows, multiple providers providing face-to-face counseling should be limited.
Acknowledgment
We acknowledge the help of other members of the Maternal-Fetal Medicine Division and Obstetric-Gynecology Department at Thomas Jefferson University, including Jason Baxter, Amanda Roman, Huda Al-Kouatly, Rebekah McCurdy, Johanna Quist-Nelson, Emily Rosenthal, Emily Oliver, Becca Pierce-Williams, Leen Al-Hafez, Laura Felder, Kerri Sendek, Alexa Herman, Keith Rychlak, Carol Folcher, and William Schlaff as well as Tracy Manuck.
Footnotes
Rupsa C. Boelig is supported by a PhRMA Foundation Faculty Development Award.
The authors report no conflict of interest.